Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 2Phase NA 1Phase 3 1

Status

Recruiting 10Unknown 7Not yet recruiting 5Terminated 4Completed 3Active not recruiting 3Withdrawn 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 3Gynecologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Ovarian Cancer Recurrent 1NSCLC 1

Interventions

Carboplatin 75Cisplatin 73Bevacizumab 64Radiotherapy 57Drug Therapy 56Capecitabine 56tislelizumab 54Oxaliplatin 54Gemcitabine 46toripalimab 45Paclitaxel 45Specimen Handling 43sintilimab 39pembrolizumab 39anlotinib 38Cyclophosphamide 33130-nm albumin-bound paclitaxel 32Magnetic Resonance Spectroscopy 27Injections 27camrelizumab 26Pemetrexed 26Surgical Procedures, Operative 25lenvatinib 23Docetaxel 23Biopsy 23apatinib 22Etoposide 22Immune Checkpoint Inhibitors 21S 1 (combination) 20Fluorouracil 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × Platinum Compounds × Clear all
NCT07358689 2026-01-22

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
120 enrolled
Thoracic

NSCLC

NCT07295132 2025-12-19

RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)

Asan Medical Center

Phase 2 Not yet recruiting
160 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT06986057 2025-05-22

Iparomlimab and Tuvonralimab Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer

Shandong Tumor Hospital

Phase 2 Not yet recruiting
28 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT06908733 2025-04-03

Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC

Liaoning Cancer Hospital & Institute

Phase 2 Not yet recruiting
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06614231 2024-09-26

Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer

Sun Yat-sen University

Phase 2 Not yet recruiting
48 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡